Any current/future new fundraising through debt or equity?

The company is currently using IPO funds to finance acquisitions, indicating no immediate need for new equity fundraising. They aim to be cash flow positive on operating cash flow, which will enable future acquisitions to be funded internally. There is no explicit mention of any new fundraising through debt in the current quarter. The company is working on tax-efficient funding structures for subsidiaries, which suggests optimization of existing funds rather than new fundraising. Management indicated that as inorganic growth needs diminish over the next 2-3 years, cash flow generation will imp

Any current/future capex/capital investment/strategic investment?

Entero Healthcare has already made significant investments in proprietary technology, including building its own customizable ERP systems integrated with platforms like Facebook and WhatsApp, and customer-facing apps. They are also developing a health tech platform to integrate directly with retailer systems. Most technology infrastructure investments are already in place, so no significant additional capex is expected in technology going forward. Future focus will be on better utilization and capitalization of existing technology to drive efficiencies such as working capital reduction. The co

Future growth expectations in sales/revenue/volumes?

Targeting 30% revenue growth in FY'26, combining both organic and inorganic growth. Organic growth remains strong at around 15%, with inorganic contributing approximately 16%, summing to a like-for-like growth of 31%. Acquisitions expected to contribute about Rs. 500 crores in revenue this year, supporting inorganic growth. Rate of acquisitions likely to taper off in the next 2-3 years as market penetration and product expansion mature. Expansion into higher-margin categories like medical devices, diagnostics, and specialty pharma to drive richer product mix and incremental growth. Deepening w

Future growth expectations in earnings/operating earnings/profits/EPS?

Entero Healthcare Solutions targets **30% revenue growth in FY'26**, combining organic and inorganic growth. EBITDA margin guidance is **4%+ for the full year FY'26**, with current Q1 margin at 3.6% expected to improve as revenue growth accelerates. Operating leverage benefits will drive margin expansion as fixed costs are stable; salary hikes are already accounted for in Q1. Gross margins improved by 83 bps YoY to 9.9%, with further procurement efficiencies and richer product mix expected. Profit after tax increased 47% YoY to Rs. 30 crores in Q1, supported by a tax-efficient structure mainta

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders in numeric terms. However, regarding acquisitions (which can be linked to future orderbook/revenue), the company targets about Rs. 500 crores of recognized acquisition revenue for the year. Four acquisition deals are in the pipeline; two already closed with revenue starting to flow from Q2, and two pending closure dependent on external factors like drug licenses. Additional deals beyond these four are under evaluation, with announcements expected within the next month. Overall, Entero Healthcare is

IN US

Sale is live|00:00:00left today

Entero Healthcare Solutions LtdQ2 FY25Retailing

Entero Healthcare Solutions Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,162P/E: 44.6Market Cap: ₹5.2K CrSector: Retailing

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→Targeting 30% revenue growth in FY'26, combining both organic and inorganic growth.
→Organic growth remains strong at around 15%, with inorganic contributing approximately 16%, summing to a like-for-like growth of 31%.
→Acquisitions expected to contribute about Rs. 500 crores in revenue this year, supporting inorganic growth.
→Rate of acquisitions likely to taper off in the next 2-3 years as market penetration and product expansion mature.
→Expansion into higher-margin categories like medical devices, diagnostics, and specialty pharma to drive richer product mix and incremental growth.
→Deepening wallet share with existing customers by expanding product range and geographic presence.
→Growth expected to be more robust from organic channels as acquisition reliance decreases.
→Operational excellence and technology integration to improve efficiency, supporting sustainable volume and sales growth.

Margin guidance

Category 2

→Entero Healthcare Solutions targets **30% revenue growth in FY'26**, combining organic and inorganic growth.
→EBITDA margin guidance is **4%+ for the full year FY'26**, with current Q1 margin at 3.6% expected to improve as revenue growth accelerates.
→Operating leverage benefits will drive margin expansion as fixed costs are stable; salary hikes are already accounted for in Q1.
→Gross margins improved by 83 bps YoY to 9.9%, with further procurement efficiencies and richer product mix expected.
→Profit after tax increased 47% YoY to Rs. 30 crores in Q1, supported by a tax-efficient structure maintaining a low effective tax rate of ~17%-18%.
→Positive operating cash flows anticipated for full FY'26 with ongoing working capital optimization targeting 60 days by year-end.
→Inorganic growth contribution (~15%-16%) will taper over next 2-3 years; organic growth is expected to sustain long-term profitability and EPS growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company is currently using IPO funds to finance acquisitions, indicating no immediate need for new equity fundraising.
→They aim to be cash flow positive on operating cash flow, which will enable future acquisitions to be funded internally.
→There is no explicit mention of any new fundraising through debt in the current quarter.
→The company is working on tax-efficient funding structures for subsidiaries, which suggests optimization of existing funds rather than new fundraising.
→Management indicated that as inorganic growth needs diminish over the next 2-3 years, cash flow generation will improve, reducing the need for external funding.
→No announcement or indication of planned new equity or debt fundraising in the near future was made during the call.

Order book

→The transcript does not explicitly mention the current or expected order book or pending orders in numeric terms.
→However, regarding acquisitions (which can be linked to future orderbook/revenue), the company targets about Rs. 500 crores of recognized acquisition revenue for the year.
→Four acquisition deals are in the pipeline; two already closed with revenue starting to flow from Q2, and two pending closure dependent on external factors like drug licenses.
→Additional deals beyond these four are under evaluation, with announcements expected within the next month.
→Overall, Entero Healthcare is on track for 30% revenue growth in FY'26, including both organic and inorganic growth, reflecting strong ongoing business momentum.
→No specific order backlog figures are disclosed in the call.

Capex plans

Yes

→Entero Healthcare has already made significant investments in proprietary technology, including building its own customizable ERP systems integrated with platforms like Facebook and WhatsApp, and customer-facing apps.
→They are also developing a health tech platform to integrate directly with retailer systems.
→Most technology infrastructure investments are already in place, so no significant additional capex is expected in technology going forward.
→Future focus will be on better utilization and capitalization of existing technology to drive efficiencies such as working capital reduction.
→The company is actively pursuing acquisitions (M&A) to expand geographic presence and product offerings, with 4 acquisitions in the pipeline and more deals being evaluated.
→Operating cash flows are a key driver for funding acquisitions going forward; currently, IPO funds are being used for acquisitions.
→The company targets to reduce working capital days by 10% by the end of the financial year as part of operational improvements.

How does Entero Healthcare Solutions Ltd rank vs peers in Retailing?

Pro feature

1Entero Healthcare Solutions Ltd

Rev 2Mar 2

See full Retailing sector rankings

Want more stocks like Entero Healthcare Solutions Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio